![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EZR |
Gene summary for EZR |
![]() |
Gene information | Species | Human | Gene symbol | EZR | Gene ID | 7430 |
Gene name | ezrin | |
Gene Alias | CVIL | |
Cytomap | 6q25.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | P15311 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7430 | EZR | GSM4909290 | Human | Breast | IDC | 3.17e-02 | 2.92e-01 | 0.2096 |
7430 | EZR | GSM4909293 | Human | Breast | IDC | 3.45e-06 | 2.15e-01 | 0.1581 |
7430 | EZR | GSM4909296 | Human | Breast | IDC | 3.02e-17 | -4.60e-01 | 0.1524 |
7430 | EZR | GSM4909297 | Human | Breast | IDC | 1.50e-09 | -5.31e-02 | 0.1517 |
7430 | EZR | GSM4909298 | Human | Breast | IDC | 5.72e-03 | 1.91e-01 | 0.1551 |
7430 | EZR | GSM4909311 | Human | Breast | IDC | 2.51e-26 | -3.87e-01 | 0.1534 |
7430 | EZR | GSM4909312 | Human | Breast | IDC | 7.48e-05 | -1.68e-01 | 0.1552 |
7430 | EZR | GSM4909317 | Human | Breast | IDC | 6.47e-05 | 3.52e-01 | 0.1355 |
7430 | EZR | GSM4909319 | Human | Breast | IDC | 6.75e-29 | -5.10e-01 | 0.1563 |
7430 | EZR | GSM4909321 | Human | Breast | IDC | 6.13e-08 | -2.49e-01 | 0.1559 |
7430 | EZR | brca1 | Human | Breast | Precancer | 2.95e-08 | 3.75e-01 | -0.0338 |
7430 | EZR | brca2 | Human | Breast | Precancer | 1.57e-03 | 1.91e-01 | -0.024 |
7430 | EZR | NCCBC14 | Human | Breast | DCIS | 6.21e-17 | 4.00e-01 | 0.2021 |
7430 | EZR | NCCBC5 | Human | Breast | DCIS | 1.57e-11 | -2.03e-01 | 0.2046 |
7430 | EZR | P1 | Human | Breast | IDC | 3.30e-15 | -1.23e-01 | 0.1527 |
7430 | EZR | P2 | Human | Breast | IDC | 8.79e-04 | 2.67e-01 | 0.21 |
7430 | EZR | DCIS2 | Human | Breast | DCIS | 1.28e-49 | 6.22e-01 | 0.0085 |
7430 | EZR | CA_HPV_1 | Human | Cervix | CC | 4.50e-03 | -2.16e-01 | 0.0264 |
7430 | EZR | CA_HPV_3 | Human | Cervix | CC | 2.09e-05 | -2.62e-01 | 0.0414 |
7430 | EZR | HSIL_HPV_1 | Human | Cervix | HSIL_HPV | 2.40e-06 | -4.56e-01 | 0.0116 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00508567 | Thyroid | HT | regulation of T cell receptor signaling pathway | 9/1272 | 41/18723 | 1.45e-03 | 1.36e-02 | 9 |
GO:000836020 | Thyroid | HT | regulation of cell shape | 21/1272 | 154/18723 | 1.74e-03 | 1.57e-02 | 21 |
GO:00508605 | Thyroid | HT | negative regulation of T cell receptor signaling pathway | 6/1272 | 22/18723 | 2.82e-03 | 2.29e-02 | 6 |
GO:00703726 | Thyroid | HT | regulation of ERK1 and ERK2 cascade | 34/1272 | 309/18723 | 3.77e-03 | 2.81e-02 | 34 |
GO:19021158 | Thyroid | HT | regulation of organelle assembly | 23/1272 | 186/18723 | 3.89e-03 | 2.88e-02 | 23 |
GO:190307626 | Thyroid | HT | regulation of protein localization to plasma membrane | 15/1272 | 104/18723 | 4.41e-03 | 3.19e-02 | 15 |
GO:003253525 | Thyroid | HT | regulation of cellular component size | 40/1272 | 383/18723 | 4.50e-03 | 3.22e-02 | 40 |
GO:190437525 | Thyroid | HT | regulation of protein localization to cell periphery | 17/1272 | 125/18723 | 4.69e-03 | 3.28e-02 | 17 |
GO:002240614 | Thyroid | HT | membrane docking | 13/1272 | 86/18723 | 5.19e-03 | 3.48e-02 | 13 |
GO:190437724 | Thyroid | HT | positive regulation of protein localization to cell periphery | 11/1272 | 69/18723 | 6.52e-03 | 4.06e-02 | 11 |
GO:003287320 | Thyroid | HT | negative regulation of stress-activated MAPK cascade | 9/1272 | 51/18723 | 6.83e-03 | 4.19e-02 | 9 |
GO:007030320 | Thyroid | HT | negative regulation of stress-activated protein kinase signaling cascade | 9/1272 | 51/18723 | 6.83e-03 | 4.19e-02 | 9 |
GO:00508515 | Thyroid | HT | antigen receptor-mediated signaling pathway | 27/1272 | 240/18723 | 6.87e-03 | 4.20e-02 | 27 |
GO:000705110 | Thyroid | HT | spindle organization | 22/1272 | 184/18723 | 6.95e-03 | 4.22e-02 | 22 |
GO:00468473 | Thyroid | HT | filopodium assembly | 10/1272 | 62/18723 | 8.54e-03 | 4.86e-02 | 10 |
GO:190307820 | Thyroid | HT | positive regulation of protein localization to plasma membrane | 10/1272 | 62/18723 | 8.54e-03 | 4.86e-02 | 10 |
GO:00024293 | Thyroid | HT | immune response-activating cell surface receptor signaling pathway | 31/1272 | 291/18723 | 8.69e-03 | 4.92e-02 | 31 |
GO:00027573 | Thyroid | HT | immune response-activating signal transduction | 31/1272 | 291/18723 | 8.69e-03 | 4.92e-02 | 31 |
GO:0009896113 | Thyroid | PTC | positive regulation of catabolic process | 278/5968 | 492/18723 | 3.35e-30 | 2.64e-27 | 278 |
GO:0031331113 | Thyroid | PTC | positive regulation of cellular catabolic process | 249/5968 | 427/18723 | 5.28e-30 | 3.58e-27 | 249 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513018 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0453018 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0467018 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0497114 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0513019 | Breast | Precancer | Pathogenic Escherichia coli infection | 38/684 | 197/8465 | 3.12e-07 | 5.81e-06 | 4.45e-06 | 38 |
hsa0453019 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0467019 | Breast | Precancer | Leukocyte transendothelial migration | 20/684 | 114/8465 | 7.26e-04 | 5.33e-03 | 4.09e-03 | 20 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0497115 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0453024 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0513024 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0497122 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
hsa0467024 | Breast | IDC | Leukocyte transendothelial migration | 21/867 | 114/8465 | 5.41e-03 | 3.13e-02 | 2.34e-02 | 21 |
hsa0481014 | Breast | IDC | Regulation of actin cytoskeleton | 36/867 | 229/8465 | 5.79e-03 | 3.13e-02 | 2.34e-02 | 36 |
hsa0453034 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0513034 | Breast | IDC | Pathogenic Escherichia coli infection | 42/867 | 197/8465 | 2.66e-06 | 3.92e-05 | 2.94e-05 | 42 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0497132 | Breast | IDC | Gastric acid secretion | 16/867 | 76/8465 | 3.80e-03 | 2.33e-02 | 1.74e-02 | 16 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 2 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EZR | SNV | Missense_Mutation | c.1140N>T | p.Lys380Asn | p.K380N | P15311 | protein_coding | deleterious(0.04) | possibly_damaging(0.456) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
EZR | SNV | Missense_Mutation | c.746C>T | p.Ser249Phe | p.S249F | P15311 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EZR | SNV | Missense_Mutation | rs528409234 | c.385G>A | p.Ala129Thr | p.A129T | P15311 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
EZR | SNV | Missense_Mutation | novel | c.1685N>A | p.Arg562Gln | p.R562Q | P15311 | protein_coding | deleterious(0.01) | possibly_damaging(0.903) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
EZR | SNV | Missense_Mutation | c.1381N>A | p.Glu461Lys | p.E461K | P15311 | protein_coding | tolerated(0.18) | benign(0.201) | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
EZR | SNV | Missense_Mutation | c.1084N>A | p.Glu362Lys | p.E362K | P15311 | protein_coding | tolerated(0.12) | benign(0.217) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
EZR | SNV | Missense_Mutation | c.1281N>T | p.Lys427Asn | p.K427N | P15311 | protein_coding | tolerated(0.06) | benign(0.033) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
EZR | SNV | Missense_Mutation | c.77G>A | p.Gly26Glu | p.G26E | P15311 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
EZR | SNV | Missense_Mutation | c.380C>T | p.Ser127Phe | p.S127F | P15311 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
EZR | SNV | Missense_Mutation | rs369743003 | c.241N>T | p.Arg81Trp | p.R81W | P15311 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7430 | EZR | CLINICALLY ACTIONABLE, KINASE | TNF-ALPHA | 15965500 | ||
7430 | EZR | CLINICALLY ACTIONABLE, KINASE | RO 31-8220 | 9124348 |
Page: 1 |